A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer

A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer - A phase I study of combination immunotherapy against mCRC

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022082

Enrollment

Registered

2016-04-26

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

combination immunotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colorectal cancer refractory to standard therapy

Exclusion criteria

Exclusion criteria: Uncontroled general complication. etc

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
1)specific CTL response 2)overall survival 3)progression-free survival 4)Response rate 5)disease control rate	—

Countries

Japan

Contacts

Public ContactShoichi Hazama

YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE Department of Translational Research and Developmental Therapeutics against Cancer

geka2dm@yamaguchi-u.ac.jp+81-836-22-2324

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026